Abstract:OBJECTIVE Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate’s effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS Type 2 diabetic patients (aged 50–75 years) with eGFR ≥30 mL/min/1.73 m2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30–59, 60–89, and ≥90 mL/min/1.73 m2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat. RESULTS Overall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80–0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30–59 mL/min/1.73 m2: 0.68 [0.47–0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m2: 0.85 [0.70–1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. CONCLUSIONS Patients with type 2 diabetes and moderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no or mild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.

Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a

Structure–activity relationship studies on quinoxalin-2(1 H )-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870

Allosteric inhibitors of the NS3 protease from the hepatitis C virus

High-level memory model with low-level pointer cast support for Jessie intermediate language

Discovery of Novel 3-Hydroxyquinazoline-2,4(1h,3h)-dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities.

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment

Increase in thyrotrophin secretion by rat pituitary autografts after infusion of hypothalamic extracts.

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization

Discovery of 2′-Α-c-methyl-2′-β-c-fluorouridine Phosphoramidate Prodrugs As Inhibitors of Hepatitis C Virus

Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking

Design and synthesis of HCV agents with sequential triple inhibitory potentials

Discovery of Novel Potent HCV NS5B Polymerase Non-Nucleoside Inhibitors Bearing a Fused Benzofuran Scaffold.

Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Re: Zhihua Lu, Guiting Lin, Amanda Reed-Maldonado, Chunxi Wang, Yung-Chin Lee, Tom F. Lue. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71:223-33.